1. Introduction
===============

Ginseng has been most widely used as herbal medicine in Eastern Asian countries, including Korea, China, and Japan. Ginseng is a species of a perennial plant belonging to the genus *Panax* in the family *Araliaceae*, and the ginseng species are only found in the northern hemisphere from Siberia to Vietnam. In general, Asian ginseng (*Panax ginseng*) and American ginseng (*Panax* *quinquefolius*) are most well-characterized, and these ginseng ginsenosides have been quantitatively and qualitatively characterized by ginsenoside profiling \[[@B001]\]. In particular, P. *ginseng* contains more than thirty pharmacologically-valuable ginsenosides \[[@B002]\]. Among them, ginsenosides such as Rg3, Rh2, Rb2, Compound K, and Rf2 are known to possess anti-cancer activities against colorectal cancer, colon cancer, hepatoma and breast cancer \[[@B003] - [@B006]\]. The ginsenosides exhibit anti-cancer activity by directly inhibiting cancer cell growth and metastasis *in vivo* and *in vitro*\[[@B007]\].The major ginsenosides, such as Rb1, Rb2 and Rg1, induce apoptosis of lung cancer via an extrinsic apoptotic pathway \[[@B008]\]. These results suggest that specific ginsenosides play critical roles in the inhibition of cancer cell proliferation.

Lung cancer, comprising of a majority of non-small-cell lung carcinomas (NSCLCs) of up to 85%, is the second leading cause of cancer death worldwide \[[@B009]\]. Thus, lung cancer is still considered as an extremely lethal cancer \[[@B010]\]. Surgical and combined therapies have contributed to reducing the mortality and the morbidity of lung cancer over last several decades; however, these therapies have limitations. Thus, complementary and alternative therapies with herbal medicine have recently been introduced in the Western medical society. However, few studies have reported on the anti-cancer activity of regular ginseng extract on a molecular biological level.

In this study, we prepared a modified regular ginseng extract (MRGX) that reinforced some gensenosides from regular ginseng butanol-extract (GBX) by using treatments with enzymes such as laminarinase and pectinase for stronger anti-cancer effect. The assessments of the gene expression proﬁles in human lung cancer samples by using cDNA microarray technology showed that some genes were down-regulated while others were up-regulated during the MRGX-treatment process. Because gene expression might change during the lung cancer cell death process, such studies should use speciﬁc components and not serum that contains a mixture of gensenosides.

2. Materials and Methods
========================

2.1. Preparation of MRGX extract
--------------------------------

The root of regular ginseng (4 yr old) was purchased from the National Agricultural Cooperative Foundation in Chuncheongnam-do, Korea. A total of 20 g of pulverized ginseng root powder was suspended in 380 ml of distilled water and then sterilized at 121℃ for 15 min. The ginseng butanol extract (GBX) contained compounds with specific anti-lung cancer activity. We used GBX as a control of regular ginseng. In addition, the suspension was treated with an aliquot of filter-sterilized commercial enzymes (laminarinase: 100 mg, pectinase: 100 mg) with equimolar ratio (1:1, specific activity unit); the mixture was then incubated at 40℃ for 2 days and evaporated to dryness at 60℃. These enzymes-modified ginseng powders were suspended in 400 ml of 80% (v/v) methanol. The suspension was treated in an ultrasound bath for 5 min and filtered through Whatman No. 2 filter paper. The filtrates were combined and evaporated to dryness at 50℃. The extract was diluted to a concentration of 10% (w/v) in 70% ethanol. In the present study, the finally-obtained sample was called the modified regular ginseng extract (MRGX).

2.2. Cell culture
-----------------

Human lung cancer (A549) cells were obtained from American Type Culture Collection (Rockville, MD). Cell lines were grown in DMEM (Dulbecco Modified Eagle's Medium, Sigma, USA) supplemented with 10% (v/v) FBS (Fetal Bovine Serum, GIBCO, NY) and 1% (w/v) penicillin- streptomycin (GIBCO, NY). The cells were incubated at 37℃ with 5% (v/v) CO~2~ for 24 h. The density of A549 cells was adjusted to 5 × 10^3^ cells/well in a 96-well plate. After a 24-h incubation, the cells were treated with MRGX at 50 ug/ml concentrations. The appropriate dose was determined by evaluating the cytotoxicity of MRGX for 24 h. To the cell solution, 10 ul of cell-counting kit-8 solution (Dojindo, Japan) was added for 1 h. Cell viability was determined by using a microplate reader (Sunrise, Tecan, Switzerland) to measuring the absorbance at 450 nm.

2.3. Microarray analysis
------------------------

For the microarray analysis of the MRGX-treated lung cancer cells, a human twin 44K cDNA chip was used for the transcription profiling analysis. Total RNA was extracted from vehicle- or MRGX-treated lung cancer cells, and cDNA probes were prepared by using reverse transcription of 50 mg of RNA in the presence of aminoallyl-dUTP, followed by coupling with Cy3 dye (vehicle) or Cy5 dye (MRGX-treated). The mixed Cy3- and Cy5-labeled RNA from lung cancer cells (A549) was hybridized with one side of the Twin Chip^TM^ Human 44K (Genocheck, Seoul, Korea), and that from MRGX-treated cells was hybridized with the other side of the chip.

Fluorescent images were quantiﬁed and normalized, as described previously \[[@B011]\]. This experiment was repeated four times. Genes were considered to be differentially expressed when the global M value, log2 (R/G), exceeded \|1.0\| (twofold) with a*P*-value \< 0.05 after a signiﬁcance analysis of the microarray (SAM). A student's *t*-test was applied to assess the statistical signiﬁcance of the differential expression of any gene between young and senescent HDFs (Human Dermal Fibroblasts) at each time point after MRGX treatment. To analyze the biological signiﬁcance of the changes, we searched the gene ontology clone annotation (<http://www.geneontolo-gy.org>) and categorized the array data into speciﬁc gene groups. To verify the microarray data, we analyzed the total RNA extracted from cells by using a semi-quantitative reverse-transcription polymerase chain reaction (RT-PCR) and 2% agarose gel electrophoresis.

2.4. Ontology-related network analysis
--------------------------------------

To study the biological functions of ontology-relate regulated genes and proteins through their interaction network, we conducted a bioinformatic protein network analysis by using an ingenuity pathways analysis (IPA, [http:// www.ingenuity.com](http:// www.ingenuity.com)). The IPA identifies the protein interaction network on the basis of a regularly-updated "Ingenuity Pathways Knowledge-base." The updatable database containing millions of individual protein-protein relationships was retrieved from the biological literature. Network generation was optimized to include as many proteins from the inputted expression profile as possible and aimed at the production of highly-connected networks.

2.5. Semi-quantitative RT-PCR confirmation
------------------------------------------

Total RNA was extracted from young and senescent cells by using an acid guanidinium thiocyanate phenol-chloroform extraction-based method. To compare the relative amounts of mRNA in young and senescent cells, we performed a semi-quantitative RT-PCR. A series of mixtures was prepared by mixing RNA from young and senescent cells as indicated, so that each mixture had the same total amount of RNA (2 μg) in a constant volume (12 μl). The RT reaction was carried out in a final volume of 20 μl by using Superscript II reverse transcriptase according to the manufacturer's protocol, and 4 μl of the final RT product mix was then PCR amplified. The primer sets used were 5'-ATCTGGCAACCCTAGTCTGC-3' and 5'-GTGCTTCCACATGTCCTCAC- 3' for IL8, 5'-GACATCATGATTGGCTTTGC- 3' and 5'-TCCTCATCGAAGTGAGCATC-3' for MMP7 and 5'-GTGAGGAAGCCCAAGCTACT-3' and 5'-ATGTCCAAGGTGGCTTCTTC-3' for PLAUR.

2.6. Western blot analysis
--------------------------

Expression levels of signaling proteins were examined by using Western blot analyses. In brief, 30 μg of denatured protein were run using 12% polyacrylamide gel electrophoresis and then transferred onto a nitrocellulose membrane. The transferred nitrocellulose membrane was stained with Ponceau S to position the proteins. The blotted membrane was blocked for 1 h with 5% (w/v) skimmed milk in TTBS (Tween-20 and Tris-buffered saline), followed by incubation with a dilution of primary antibodies (Cell Signal, Boston, USA), including interleukin-8 (IL-8), matrix metallopeptidase 7 (MMP7) and plasminogen activator, urokinase receptor (PLAUR), at room temperature for 2 h or at 4℃ overnight. The membrane was washed three times for 5 min with 0.1% (v/v) TTBS before incubation with horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG or HRP-conjugated rabbit anti-goat IgG with a 1:2000 dilution in TBS containing 5% (w/v) skimmed milk at room temperature for 1 h. The membrane was rinsed three times with TBS-0.1% (v/v) Tween-20 for 5 min. The Pierce^®^ ECL system (Thermo Scientific, San Jose, CA) was used to develop the proteins on an X-ray film (Kodak, Seoul, Korea). The expression levels of proteins were quantitatively analyzed with GAPDH as an internal control.

3. Result
=========

3.1. Analysis of MRGX related gene expression in lung cancer cells
------------------------------------------------------------------

To analyze the MRGX-related gene expression in lung cancer cells, we used a cDNA microarray analysis approach. Microarray data were filtered and combined using gene symbols; then, network analyses were performed. The clustered microarray data showed that groups of genes in lung cancer and MRGX-treated lung cancer cells were regulated differently by 50 mM of MRGX. Genes with at least one global M \|1.0\| are shown in Table [1](#T001){ref-type="table"} and [2](#T002){ref-type="table"}. A total of 109 were ultimately identified and categorized in terms of their cellular functions by using gene ontology and IPA annotation: The Venn-diagram for migration (45%), metabolism (45%), and cell death and survival (10%) are shown in Fig [1](#F001){ref-type="fig"} The relative abundances of the regulated genes between lung and MRGX-treated lung cancer cells determined by using a semi-quantitative analysis, as described previously \[[@B012]\], are listed in Table [1](#T001){ref-type="table"}. Based on the criterion of a fold change \> 1.0, 80 were up-regulated (Fig. 1A) whereas 29 were down-regulated in MRGX-treated lung cancer cells (Fig [1](#F001){ref-type="fig"} B) compared to lung cancer.

3.2. Network analysis based on Gene Ontology analysis
-----------------------------------------------------

To explore key MRGX-related proteins in the gene ontology analysis of gene functions, we used IPA to query 109 proteins belonging to the proteins up- and down-regulated by MRGX, resulting in a distinct interconnected network of 21 proteins (Fig [2](#F002){ref-type="fig"}). There were quantitative and qualitative alterations in MRGX-treated lung cancer cells between the regulation groups. Among them, interleukin 8 (IL8) was identified as the center of the MRGX-related protein network in lung cancer cells. IL-8 is a lung giant-cell carcinoma-derived chemotactic protein that binds CXCR1 and CXCR2 \[[@B013]\]. In the present study, IL-8 is one of critical chemo-attractants responsible for leukocyte recruitment, cancer proliferation, and angiogenesis, and the potential mechanism of IL-8 production from human non-small-cell lung cancer was investigated \[[@B014]\]. IL-8 was decreased dramatically in the MRGX-treated lung cancer cells. The protein-protein network analysis suggests that IL-8 is a major protein that interacts with multiple proteins and that it is directly or indirectly down-regulated or up-regulated in MRGX-treat lung cancer cells. IL-8-linked proteins include chemokine (C-X-C motif) ligand 2 (CXCl2), MMP7 and PLAUR. PLAUR plays a key role in lung cancer \[[@B015]\]. However, the detailed mechanism has not been studied in lung cancer. Herein, the level of IL-8 in the MRGX-treated lung-cancer cells was 1.9-fold down-regulated while PLAUR was up-regulated. The accumulation of PLAUR has been associated with lung cancer therapy.

###### Up-regulated gene list

  Genbank Accession ID   Gene Symbol   Protein Name                                                                     Fold Change
  ---------------------- ------------- -------------------------------------------------------------------------------- -------------
  NM_001159699           FHL1          four and a half LIM domains 1                                                    2.158241
  NM_001184717           TIPARP        TCDD-inducible poly (ADP-ribose) polymerase                                      1.982939
  NM_000612              IGF2          insulin-like growth factor 2 somatomedin A                                       1.871624
  NM_002203              ITGA2         integrin alpha 2 (CD49B alpha 2 subunit of VLA-2 receptor)                       1.83122
  NM_002526              NT5E          5\'-nucleotidase ecto (CD73)                                                     1.808669
  NM_032141              NSRP1         nuclear speckle splicing regulatory protein 1                                    1.734883
  NM_000104              CYP1B1        cytochrome P450, family 1, subfamily B, polypeptide 1                            1.694663
  NM_000104              UBASH3B       ubiquitin associated and SH3 domain containing B                                 1.555049
  NM_003822              NR5A2         nuclear receptor subfamily 5, group A, member 2                                  1.503484
  NM_000104              CYP1B1        cytochrome P450, family 1, subfamily B, polypeptide 1                            1.493132
  NM_005891              ACAT2         acetyl-CoA acetyltransferase 2                                                   1.490562
  NM_004487              GOLGB1        golgin B1                                                                        1.477885
  NM_005633              SOS1          son of sevenless homolog 1                                                       1.463831
  NM_004454              ETV5          ets variant 5                                                                    1.445291
  NM_001723              DST           dystonin                                                                         1.432908
  NM_001137550           LRRFIP1       leucine rich repeat (in FLII) interacting protein 1                              1.410612
  NM_004925              AQP3          aquaporin 3 (Gill blood group)                                                   1.374904
  NM_001173463           KIF21A        kinesin family member 21A                                                        1.363929
  NM_001105244           PTPRM         protein tyrosine phosphatase, receptor type, M                                   1.351404
  NM_002483              CEACAM6       carcinoembryonic antigen-related cell adhesion molecule 6                        1.34875
  NM_022118              RBM26         RNA binding motif protein 26                                                     1.333552
  NM_003861              DCAF5         DDB1 and CUL4 associated factor 5                                                1.315943
  NM_001023587           ABCC5         ATP-binding cassette, sub-family C (CFTR/MRP), member 5                          1.313605
  NM_003344              UBE2H         ubiquitin-conjugating enzyme E2H                                                 1.287242
  NM_001174087           NCOA3         nuclear receptor coactivator 3                                                   1.286065
  NM_001946              DUSP6         dual specificity phosphatase 6                                                   1.253699
  NM_003870              IQGAP1        IQ motif containing GTPase activating protein 1                                  1.250989
  NM_001193455           NSUN2         NOP2/Sun RNA methyltransferase family, member 2                                  1.24729
  NM_001025356           ANO6          anoctamin 6                                                                      1.2465
  NM_021925              C2orf43       chromosome 2 open reading frame 43                                               1.242904
  NM_001098272           HMGCS1        3-hydroxy-3-methylglutaryl-CoA synthase 1 (soluble)                              1.210537
  NM_005063              SCD           stearoyl-CoA desaturase (delta-9-desaturase)                                     1.201598
  NM_014331              SLC7A11       solute carrier family 7 (anionic amino acid transporter light chain) member 11   1.186217
  NM_001146276           NCEH1         neutral cholesterol ester hydrolase 1                                            1.185191
  NM_000693              ALDH1A3       aldehyde dehydrogenase 1 family, member A3                                       1.183801
  NM_004100              EYA4          eyes absent homolog 4                                                            1.172664
  NM_001032281           TFPI          tissue factor pathway inhibitor                                                  1.171704
  NM_001008938           CKAP5         cytoskeleton associated protein 5                                                1.171153
  NM_001142568           BBX           bobby sox homolog                                                                1.168988
  NM_001113239           HIPK2         homeodomain interacting protein kinase 2                                         1.164367
  NM_016284              CNOT1         CCR4-NOT transcription complex, subunit 1                                        1.162079
  NM_004775              B4GALT6       UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypeptide 6                1.160644
  NM_014646              LPIN2         lipin 2                                                                          1.14518
  NM_172037              RDH10         retinol dehydrogenase 10 (all-trans)                                             1.144987
  NM_001005376           PLAUR         plasminogen activator, urokinase receptor                                        1.13818
  NM_001077181           CDC14B        cell division cycle 14B                                                          1.135517
  NM_001083592           ROR1          receptor tyrosine kinase-like orphan receptor 1                                  1.135517
  NM_007350              PHLDA1        pleckstrin homology-like domain, family A, member 1                              1.131633
  NM_020738              KIDINS220     kinase D-interacting substrate, 220kDa                                           1.11258
  NM_017694              MFSD6         major facilitator superfamily domain containing 6                                1.110798
  NM_031897              CACNG6        calcium channel, voltage-dependent, gamma subunit 6                              1.094036
  NM_001130107           KLC1          kinesin light chain 1                                                            1.093194
  NM_001174159           SH2D4A        SH2 domain containing 4A                                                         1.081308
  NM_012090              MACF1         microtubule-actin crosslinking factor 1                                          1.078294
  NM_001025081           MBP           myelin basic protein                                                             1.077327
  NM_001001894           TTC3          tetratricopeptide repeat domain 3                                                1.068548
  NM_001190438           NCOR1         nuclear receptor corepressor 1                                                   1.068334
  NM_001077484           SLC38A1       solute carrier family 38, member 1                                               1.066673
  NM_001962              EFNA5         ephrin-A5                                                                        1.064771
  NM_014827              ZC3H11A       zinc finger CCCH-type containing 11A                                             1.058277
  NM_015554              GLCE          glucuronic acid epimerase                                                        1.051527
  NM_012197              RABGAP1       RAB GTPase activating protein 1                                                  1.04982
  NM_001184998           KIAA0430      KIAA0430                                                                         1.049638
  NM_015635              GAPVD1        GTPase activating protein and VPS9 domains 1                                     1.048175
  NM_152641              ARID2         AT rich interactive domain 2                                                     1.044772
  NM_203365              RAPH1         Ras association (RalGDS/AF-6) and pleckstrin homology domains 1                  1.041108
  NM_145693              LPIN1         lipin 1                                                                          1.039824
  NM_004462              FDFT1         farnesyl-diphosphate farnesyltransferase 1                                       1.03898
  NM_024817              THSD4         thrombospondin, type I, domain containing 4                                      1.038791
  NM_001002860           BTBD7         BTB (POZ) domain containing 7                                                    1.038677
  NM_001081550           THOC2         THO complex 2                                                                    1.035132
  NM_001128626           SPIRE1        spire homolog 1                                                                  1.026552
  NM_001197030           ANKHD1        ankyrin repeat and KH domain containing 1                                        1.023268
  NM_001142614           EHBP1         EH domain binding protein 1                                                      1.02271
  NM_014689              DOCK10        dedicator of cytokinesis 10                                                      1.013887
  NM_004462              FDFT1         farnesyl-diphosphate farnesyltransferase 1                                       1.012972
  NM_015491              PNISR         PNN-interacting serine/arginine-rich protein                                     1.012695
  NM_004864              GDF15         growth differentiation factor 15                                                 1.008396
  NM_001031685           TP53BP2       tumor protein p53 binding protein, 2                                             1.004355
  NM_016653              ZAK           sterile alpha motif and leucine zipper containing kinase AZK                     1.001137

###### Down-regulated gene list

  Genbank Accession ID   Gene Symbol   Protein Name                                                                                  Fold Change
  ---------------------- ------------- --------------------------------------------------------------------------------------------- -------------
  NM_000585              IL15          interleukin 15                                                                                -1.00511
  NM_006763              BTG2          BTG family, member 2                                                                          -1.01812
  NM_005195              CEBPD         CCAAT/enhancer binding protein (C/EBP), delta                                                 -1.02364
  NM_001166599           FAM122B       family with sequence similarity 122B                                                          -1.02554
  NM_152603              ZNF567        zinc finger protein 567                                                                       -1.02634
  NM_000366              TPM1          tropomyosin 1 (alpha)                                                                         -1.03063
  NM_001416              EIF4A1        eukaryotic translation initiation factor 4A1                                                  -1.03982
  NM_001008405           BCAP29        B-cell receptor-associated protein 29                                                         -1.05437
  NM_001145275           ZFY           zinc finger protein, Y-linked                                                                 -1.06241
  NM_152487              TMEM56        transmembrane protein 56                                                                      -1.0712
  NM_002423              MMP7          matrix metallopeptidase 7 (matrilysin, uterine)                                               -1.07991
  NM_000598              IGFBP3        insulin-like growth factor binding protein 3                                                  -1.08553
  NM_004617              TM4SF4        transmembrane 4 L six family member 4                                                         -1.09854
  NM_006761              YWHAE         tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, epsilon polypeptide   -1.11487
  NM_014696              GPRIN2        G protein regulated inducer of neurite outgrowth 2                                            -1.13021
  NM_004428              EFNA1         ephrin-A1                                                                                     -1.18932
  NM_020374              C12orf4       chromosome 12 open reading frame 4                                                            -1.19108
  NM_001143668           AMIGO2        adhesion molecule with Ig-like domain 2                                                       -1.20343
  NM_144643              SCLT1         sodium channel and clathrin linker 1                                                          -1.2175
  NM_003821              RIPK2         receptor-interacting serine-threonine kinase 2                                                -1.3159
  NM_002522              NPTX1         neuronal pentraxin I                                                                          -1.36692
  NM_006528              TFPI2         tissue factor pathway inhibitor 2                                                             -1.45019
  NM_005949              MT1F          metallothionein 1F                                                                            -1.45041
  NM_001511              CXCL1         chemokine (C-X-C motif) ligand 1                                                              -1.74981
  NM_000584              IL8           interleukin 8                                                                                 -1.94821
  NM_002090              CXCL3         chemokine (C-X-C motif) ligand 3                                                              -2.2981
  NM_002089              CXCL2         chemokine (C-X-C motif) ligand 2                                                              -2.38018
  AF432419               C75F          C75F                                                                                          -5.11758
  AY227436               DSP1          drug-sensitive protein 1                                                                      -6.3106
  AB014766               DERP12        dermal papilla derived protein 12                                                             -6.74444

![Venn diagram of a 2-fold changed gene based on cellular function using gene ontology. Venn diagrams show (A) genes up-regulated in MRGX-treated lung cancer cells by migration, metabolism, and cell death and survival in the microarray analysis, and (B) genes down-regulated in the microarray analysis.](2093-6966-v16-n03-030-g001){#F001}

4. Discussion
=============

Microarray analyses may result in biased data, and inconsistent results are often obtained when different methods are used. Therefore, the data need to be validated with a specific method. Because we measured gene expression, we wanted to validate our screening results with conventional methods such as RT-PCR and Western blots. We selected genes from each of the two up- and down-regulated group of genes for validation by using semi-quantitative RT-PCR and Western blot analyses. Four genes were selected based on their high fold-change (a large number) in the analysis and the availability of commercial antibodies. IL- 8, MMP7and PLAUR are examples of up- and down-regulated genes. The mRNA levels of IL-8 and MMP7 were decreased in the MRGX-treated lung cancer cells, and the protein levels of IL-8 and MMP7 also decreased. The semi-quantitative PCR and Western blot results showed that PLAUR was increased (Fig [3](#F003){ref-type="fig"}).

5. Conclusion
=============

In conclusion, most MRGX-responsive genes are up-regulated transiently in A549 cells, but are down-regulated in a sustained manner in lung cancer cells. These genes might be involved in the altered MRGX responsiveness observed during the cancer migration and metabolism processes. The roles of these genes in MRGX responses, including the cell cycle and cell growth, should be evaluated in further studies by modulating their expressions.

![Network analysis based on a gene ontology analysis. Two-fold changed total proteins regulated by MRGX were queried by IPA, resulting in a distinct interconnected network of 21 proteins.](2093-6966-v16-n03-030-g002){#F002}

![Validation of microarray analysis results by using Western blot and RT-PCR analyses. Expressions of IL8 and MMP were examined by using a Western blot analysis with an anti-IL8 and MMP7 antibody (left panel) and by using a RT-PCR analysis (right panel). Expression of PLAUR was examined as described above. Beta-actin protein was used as a loading control for Western blot, and GAPDH was used as a normalization control forsemi-quantitative PCR.](2093-6966-v16-n03-030-g003){#F003}
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